- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00744991
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
September 23, 2020 updated by: Eli Lilly and Company
A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma
The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
Study Overview
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
California
-
Los Angeles, California, United States, 90095
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Stanford, California, United States, 94305
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Florida
-
Miami, Florida, United States, 33136
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Orlando, Florida, United States, 32806
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Columbus, Ohio, United States, 43210
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Oregon
-
Portland, Oregon, United States, 97239
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Pittsburgh, Pennsylvania, United States, 15213
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Texas
-
Houston, Texas, United States, 77030
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed mycosis fungoides or Sezary Syndrome.
- Stage IB to IVB disease at screening.
- Recurrent or refractory disease after at least 1 prior systemic therapy.
Have adequate organ function defined as:
- Hepatic: total bilirubin ≤1.5 times the upper limit of normal (ULN); alanine transaminase/aspartate transaminase (ALT/AST) ≤2.5 times the ULN.
- Renal: serum creatinine ≤1.5 times the ULN.
- Adequate bone marrow reserve: platelets ≥75 * 10^9/Liters (L); absolute neutrophil count (ANC) ≥1.0 * 10^9/L.
- At least 30 days must have passed since other treatment for CTCL.
Exclusion Criteria:
- Receiving concurrent treatment for CTCL.
- Unable to swallow tablets.
- Receiving high potency oral or topical steroids. Low potency oral steroid may be permitted in participants who have been on a stable dose for at least 4 weeks prior to screening. Oral or topical antihistamine is allowed.
- Unable to discontinue use of carbamazepine, phenobarbital, or phenytoin.
- Have a serious concomitant systemic disorder or Human Immunodeficiency Virus (HIV).
- Have a serious cardiac condition such as myocardial infarction within past 6 months, angina, or heart disease as defined by the New York Heart Association (NYHA) Class III or IV.
- Have electrocardiogram (ECG) abnormalities.
- Are pregnant or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Enzastaurin
Open Label
|
1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Among Mycosis Fungoides (MF) and Sezary Syndrome (SS) Participants (Response Rate)
Time Frame: Baseline to measured Progressive Disease (PD) [up to 9 cycles (28-day cycles)]
|
Response rate is percentage of participants with confirmed CR or PR as per modified Severity-Weighted Assessment Tool (mSWAT) for MF group; mSWAT and Sezary count for SS group.
mSWAT is a weighted sum of percent (%) of total body surface area attributed to skin lesions which yield a mSWAT score [0 (unaffected) to 400 (severely affected)] transformed into responses.
As per mSWAT (CR: No detectable malignant disease for ≥4 weeks; PR: ≥50% mSWAT score reduction from baseline).
Sezary cells percentage in lymphocytes measured using flow cytometry.
As per Sezary count (CR: Sezary cells <5%; PR: ≥50% reduction in Sezary cells from baseline).
Response rate is calculated as total number of participants with CR or PR from the start of study treatment until PD or recurrence divided by the number of participants treated, then multiplied by 100.
|
Baseline to measured Progressive Disease (PD) [up to 9 cycles (28-day cycles)]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response for Responding Participants
Time Frame: Time of response to PD [up to 9 cycles (28-day cycles)]
|
Time from first confirmed response [Complete Response (CR) or Partial Response (PR)] until Progressive Disease (PD) as per mSWAT for MF group; mSWAT and Sezary count for SS group.
mSWAT: weighted sum of percent (%) of total body surface area attributed to skin lesions; scores [0 (unaffected) to 400 (severely affected)] transformed into responses.
As per mSWAT (CR: No detectable malignant disease for ≥4 weeks; PR: ≥50% reduction in mSWAT score from baseline; PD: ≥25% of mSWAT score from nadir).
Sezary cells percentage in lymphocytes measured using flow cytometry.
As per Sezary count (CR: Sezary cells <5%; PR: ≥50% reduction in Sezary cells from baseline; PD: ≥40% of Sezary cells from nadir).
Responders or those who died without PD were censored at date of last progression-free disease assessment.
Responders who received subsequent systemic anticancer therapy were censored at date of last progression-free disease assessment prior to post-discontinuation therapy.
|
Time of response to PD [up to 9 cycles (28-day cycles)]
|
Time to Progression
Time Frame: Baseline to measured PD [up to 9 cycles (28-day cycles)]
|
Elapsed time from enrollment (baseline) to date of Progressive Disease (PD) as per mSWAT for Mycosis Fungoides (MF) group; mSWAT and Sezary count for Sezary Syndrome (SS) group.
mSWAT: weighted sum of percent (%) of total body surface area attributed to skin lesions; scores [0 (unaffected) to 400 (severely affected)] transformed to responses.
PD: ≥25% of mSWAT score from nadir.
Sezary cells percentage in lymphocytes measured using flow cytometry.
PD: ≥40% Sezary cells from nadir.
Responders or those who died without PD were censored at the date of the last progression-free disease assessment.
Responders who received subsequent systemic anticancer therapy were censored at the date of the last progression-free disease assessment prior to post-discontinuation therapy.
|
Baseline to measured PD [up to 9 cycles (28-day cycles)]
|
Time to Objective Response for Responding Participants
Time Frame: Baseline to confirmed response [up to 9 cycles (28-day cycles)]
|
Elapsed time from date of study enrollment (baseline) to first evidence of Complete Response (CR) or Partial Response (PR) as per mSWAT for Mycosis Fungoides (MF) group; mSWAT and Sezary count for Sezary Syndrome (SS) group.
mSWAT: weighted sum of percent (%) of total body surface area attributed to skin lesions; scores [0 (unaffected) to 400 (severely affected)] transformed into responses.
As per mSWAT (CR: No detectable malignant disease for ≥4 weeks.
PR: ≥50% mSWAT score reduction from baseline).
Sezary cells percentage in lymphocytes measured using flow cytometry.
As per Sezary count (CR: Sezary cells <5%; PR: ≥50% reduction in Sezary cells from baseline).
Response must be confirmed, but the time to objective response ended at the first assessment.
Participants who were not confirmed responders did not contribute to the time to objective response calculation.
|
Baseline to confirmed response [up to 9 cycles (28-day cycles)]
|
European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Utility Score United States (US) Index (Participant-Reported Measure of Health-State Utility)
Time Frame: Baseline to study completion [up to 9 cycles (28-day cycles)], end of treatment reported
|
EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument.
The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (1 (no problem), 2 (some problems), and 3 (extreme problems)).
These combinations of attributes were converted into a single summary health-state index score by applying weights from the US-specific value set to the scoring algorithm.
The EQ-5D US value set of health state index scores ranged from 0 (worst imagined health state) to 1 (best imagined health state).
|
Baseline to study completion [up to 9 cycles (28-day cycles)], end of treatment reported
|
Pruritus 5-Item Severity Assessment Questionnaire (Participant-Reported Experiences With Pruritus)
Time Frame: Baseline to study completion [up to 9 cycles (28-day cycles)], end of treatment reported
|
Participants assessed their present level of itch through the use of an 11-point numeric rating scale anchored at 0 (no itch) and 10 (itch as bad as can be imagined).
|
Baseline to study completion [up to 9 cycles (28-day cycles)], end of treatment reported
|
Change From Baseline in Itchy Quality of Life (QoL) Domain and Total Scores (Participant-Reported Experiences With Pruritus)
Time Frame: Baseline, up to study completion [up to 9 cycles (28-day cycles)], end of treatment reported
|
The Itchy QoL is a non-validated 22-item questionnaire designed to assess pruritus-associated symptoms with a 7-day recall using 3 domains: Emotions (9 items), Functions (7 items) and Symptoms domain (6 items).
Each Itchy QoL item was evaluated by level of itch frequency through the use of a 5-point adjectival scale 1 (never), 2 (rarely), 3 (sometimes), 4 (often), 5 (all the time).
Unweighted means were calculated individually for the 3 domains each with scores range from 1 to 5 and the total score is expressed as the mean of the three dimension scores and ranges from 1 (no itch) to 5 (worst imaginable itch).
|
Baseline, up to study completion [up to 9 cycles (28-day cycles)], end of treatment reported
|
Number of Participants With Adverse Events (AEs) or Deaths (Safety and Tolerability of Enzastaurin)
Time Frame: Baseline to study completion [up to 9 cycles (28-day cycles)] plus 30-day safety follow-up
|
Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality, deaths during the study including 30 days after treatment discontinuation.
A summary of SAEs and other non-SAEs regardless of causality is located in the Reported Adverse Events module.
|
Baseline to study completion [up to 9 cycles (28-day cycles)] plus 30-day safety follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (Actual)
January 1, 2010
Study Completion (Actual)
February 1, 2010
Study Registration Dates
First Submitted
August 29, 2008
First Submitted That Met QC Criteria
August 29, 2008
First Posted (Estimate)
September 1, 2008
Study Record Updates
Last Update Posted (Actual)
October 19, 2020
Last Update Submitted That Met QC Criteria
September 23, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11496
- H6Q-MC-JCCB (Other Identifier: Eli Lilly and Company)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous T-Cell Lymphoma
-
University of WashingtonNational Cancer Institute (NCI)TerminatedCutaneous T-cell Lymphoma Stage I | Cutaneous T-cell Lymphoma Stage II | Cutaneous T-cell Lymphoma Stage III | Cutaneous T-cell Lymphoma Stage IVUnited States
-
Kyowa Kirin, Inc.Active, not recruitingCutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, RelapsedUnited States, United Kingdom, Spain, France, Italy
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedCutaneous T-cell Lymphoma | Peripheral T-cell LymphomaUnited States
-
Eisai Co., Ltd.CompletedCutaneous T-cell Lymphoma | Peripheral T-cell LymphomaJapan
-
Karyopharm Therapeutics IncTerminatedCutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)Australia, Singapore
-
John ReneauActive, not recruitingRecurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditionsUnited States
-
Falo, Louis, MDActive, not recruitingCutaneous T Cell LymphomaUnited States
-
CelgeneCelgene CorporationCompletedCutaneous T-cell LymphomaUnited States, France, Germany, Poland, Russian Federation, United Kingdom
-
University of Michigan Rogel Cancer CenterWithdrawnCutaneous T Cell LymphomaUnited States
Clinical Trials on Enzastaurin
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedT-Cell Lymphoma | B-Cell LymphomaMexico, United States, Australia, Brazil, Peru
-
Eli Lilly and CompanyCompletedMantle-Cell LymphomaAustralia, France, Germany, Netherlands
-
Eli Lilly and CompanyCompletedNeoplasms | CancerUnited States
-
Eli Lilly and CompanyCompletedLymphoma, FollicularUnited States, Germany
-
Eli Lilly and CompanyCompletedLymphoma, Malignant | Solid TumorChina
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States
-
Aytu BioPharma, Inc.ParexelSuspendedVascular Ehlers-Danlos SyndromeUnited States
-
Eli Lilly and CompanyGynecologic Oncology GroupCompletedNeoplasms | Carcinoma | Ovarian CancerUnited States
-
Eli Lilly and CompanyCompletedMultiple Myeloma | Waldenstrom's MacroglobulinemiaFrance, United States